Is a nadir bone marrow required and, if so, what to do with residual disease?
- 31 December 2011
- journal article
- review article
- Published by Elsevier BV in Best Practice & Research Clinical Haematology
- Vol. 24 (4), 527-532
- https://doi.org/10.1016/j.beha.2011.09.009
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Response-Guided Induction Therapy in Pediatric Acute Myeloid Leukemia With Excellent Remission RateJournal of Clinical Oncology, 2011
- Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosisCancer, 2010
- Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemiaHaematologica, 2008
- The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemiaAmerican Journal of Hematology, 2007
- Risk-adapted induction and consolidation therapy in adults with de novo AML aged ≤ 60 years: results of a prospective multicenter trialAnnals of Hematology, 2004
- Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 TrialBlood, 2003
- Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup studyBritish Journal of Haematology, 1989
- Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant diseaseLeukemia Research, 1988